东宝生物(300239) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥213,972,459.55, a decrease of 6.84% compared to the same period last year[6]. - Net profit attributable to shareholders for Q3 2023 was ¥30,257,596.62, an increase of 1.50% year-on-year[6]. - For the first three quarters of 2023, the company achieved operating revenue of RMB 734,671,103.09, representing a year-on-year increase of 4.05%[22]. - The net profit attributable to shareholders of the listed company was RMB 95,261,690.05, reflecting a year-on-year growth of 8.52%[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 89,766,473.80, with a year-on-year increase of 8.05%[22]. - The company's net profit attributable to shareholders increased to CNY 331,352,738.98 from CNY 251,524,726.48, reflecting a growth of about 31.7%[28]. - The net profit for the third quarter of 2023 was CNY 101,932,609.79, an increase of 10.3% compared to CNY 92,439,092.18 in the same period last year[31]. - The total profit for the quarter was CNY 119,002,673.77, up from CNY 107,878,453.53, which is an increase of 10.4%[31]. Assets and Liabilities - The total assets at the end of Q3 2023 reached ¥2,713,125,525.40, reflecting a growth of 17.55% compared to the end of the previous year[6]. - As of September 30, 2023, the total assets of Baotou Dongbao Biotechnology Co., Ltd. reached CNY 2,713,125,525.40, an increase from CNY 2,308,113,622.60 at the beginning of the year[26]. - The company's total current assets increased to CNY 1,363,079,739.40 from CNY 1,023,890,791.80, reflecting a growth of approximately 33.2%[26]. - The total liabilities rose to CNY 838,743,897.90, compared to CNY 552,258,173.95 at the start of the year, indicating a significant increase of about 51.9%[27]. Cash Flow - The cash flow from operating activities for the year-to-date period was ¥130,287,710.94, an increase of 2.81%[6]. - The net cash flow from operating activities was CNY 130,287,710.94, compared to CNY 126,730,842.75 in the previous year, indicating a slight increase of 4.0%[32]. - The company reported a net cash inflow from financing activities of CNY 320,156,942.98, significantly higher than CNY 127,868,845.94 in the same quarter last year, marking an increase of 150.2%[33]. - The total cash and cash equivalents at the end of the period reached CNY 712,939,787.40, up from CNY 284,292,166.88, showing a growth of 150.1%[33]. Shareholder Information - The top shareholder, Qingdao Guoen Technology Co., Ltd., holds 21.18% of the shares, amounting to 125,711,022 shares, with 88,000,000 shares pledged[18]. - The total number of common stock shareholders at the end of the reporting period was 25,259[17]. - The company has a total of 79,520,464 restricted shares, with 1,476,169 shares released during the period[21]. Investment and Projects - The company issued convertible bonds during the reporting period, resulting in a significant increase in cash flow from financing activities by 150.38% to ¥320,156,942.98[16]. - The company plans to issue 4,550,000 convertible bonds at a face value of RMB 100 each, raising a total of RMB 455,000,000[24]. - The actual net amount raised from the bond issuance, after deducting related expenses, is RMB 442,263,443.42[24]. - The construction in progress increased by 77.62% to ¥284,718,051.61, attributed to investments in a new intelligent capsule project[11]. Operating Costs and Expenses - The total operating costs increased to CNY 618,064,708.07 from CNY 603,614,933.33, which is an increase of about 2.4%[29]. - Research and development expenses for the period were CNY 19,739,946.75, compared to CNY 17,057,544.09 in the previous period, marking an increase of approximately 15.7%[29]. Other Financial Metrics - The company's basic earnings per share for Q3 2023 was ¥0.0510, up by 1.59% from the previous year[6]. - Basic and diluted earnings per share increased to CNY 0.1605 from CNY 0.1479, representing a rise of 17.0%[32]. - The company recorded a net investment loss of ¥3,647,909.07, which was 407.39% higher than the previous period, primarily due to higher losses from long-term equity investments[13]. - The company incurred a credit impairment loss of CNY 510,785.46, while the asset impairment loss was CNY 19,226.86, indicating challenges in asset management[31].